Article

Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that there is a tremendous amount of waste in the system.

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that there is a tremendous amount of waste in the system.

"Waste in the system is created by ineffective technology and claims processing that is very cumbersome for both payers and providers," says Dr Feinberg.

Related Videos
Dr Emma Achola-Kothani
Marla Black Morgan, MD, Phoebe Neurology Associates
Christine Funke, MD
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Dr Emma Achola-Kothari
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Related Content
AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com
May 21st 2025

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

Laura Joszt, MA Eileen Peng, PharmD
The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.
Managed Care Cast
May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville
Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
FDA Approved | Image credit: chrisdorney – stock.adobe.com
May 14th 2025

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

Hayden E. Klein
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
managed care cast logo
May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS
Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health
May 14th 2025

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

Pearl Steinzor
RWJBarnabas Health and Rutgers Cancer Institute unveil the Jack & Sheryl Morris Cancer Center—1 of only 13 freestanding cancer hospitals in the US.
At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com
May 14th 2025

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

Rose McNulty
Remote symptom monitoring in cancer care reduces hospitalizations, enhances value-based care, and supports diverse patient populations, according to new findings.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo